Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Lammers

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Breast (Edinburgh, Scotland)|February 26, 2017
Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilarsChristian Jackisch, Philip Lammers, Ira Jacobs
Pharmaceuticals (Basel, Switzerland)|September 19, 2014
Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging MarketsPhilip Lammers, Carmen Criscitiello, Giuseppe Curigliano, et al.
EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [Et Al.]|February 24, 2016
Biosimilars: Extrapolating the evidence. A roundtable discussionBradley J Monk, Morton Coleman, Philip Lammers, et al.
International Journal of Molecular Sciences|August 1, 2018
Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 DiabetesJosiah Ochieng, Gladys Nangami, Amos Sakwe, et al.
FEBS Letters|September 5, 2018
Extracellular histones are the ligands for the uptake of exosomes and hydroxyapatite-nanoparticles by tumor cells via syndecan-4Josiah Ochieng, Gladys Nangami, Amos Sakwe, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 1, 2025
Barriers to Lung Cancer Screening in a Multi-Disciplinary Thoracic Oncology Program Cohort: Effects of an Incidental Pulmonary Nodule ProgramWei Liao, Meredith A Ray, Anita Patel, et al.
JTO Clinical and Research Reports|September 30, 2021
Survival Impact of an Enhanced Multidisciplinary Thoracic Oncology Conference in a Regional Community Health Care SystemMeredith A Ray, Nicholas R Faris, Carrie Fehnel, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Breast (Edinburgh, Scotland)|February 26, 2017
Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilarsChristian Jackisch, Philip Lammers, Ira Jacobs
Pharmaceuticals (Basel, Switzerland)|September 19, 2014
Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging MarketsPhilip Lammers, Carmen Criscitiello, Giuseppe Curigliano, et al.
EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [Et Al.]|February 24, 2016
Biosimilars: Extrapolating the evidence. A roundtable discussionBradley J Monk, Morton Coleman, Philip Lammers, et al.
International Journal of Molecular Sciences|August 1, 2018
Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 DiabetesJosiah Ochieng, Gladys Nangami, Amos Sakwe, et al.
FEBS Letters|September 5, 2018
Extracellular histones are the ligands for the uptake of exosomes and hydroxyapatite-nanoparticles by tumor cells via syndecan-4Josiah Ochieng, Gladys Nangami, Amos Sakwe, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 1, 2025
Barriers to Lung Cancer Screening in a Multi-Disciplinary Thoracic Oncology Program Cohort: Effects of an Incidental Pulmonary Nodule ProgramWei Liao, Meredith A Ray, Anita Patel, et al.
JTO Clinical and Research Reports|September 30, 2021
Survival Impact of an Enhanced Multidisciplinary Thoracic Oncology Conference in a Regional Community Health Care SystemMeredith A Ray, Nicholas R Faris, Carrie Fehnel, et al.
Pageof 1